Indications for PET/CT in the Head and Neck

Otolaryngologic Clinics of North America

Volumn 41, Issue 1, 2008, Pages 23-49

  Agarwal, Vikas ^a   Branstetter IV, Barton F ^a   Johnson, Jonas T ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b University of Pittsburgh School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

CANCER RADIOTHERAPY; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; HEAD AND NECK CANCER; HEALTH SURVEY; HODGKIN DISEASE; HUMAN; POSITRON EMISSION TOMOGRAPHY; RADIOSURGERY; REVIEW; SQUAMOUS CELL CARCINOMA; THYROID CARCINOMA; UNITED STATES;

CARCINOMA, SQUAMOUS CELL; FOLLOW-UP STUDIES; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PATIENT CARE PLANNING; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 38749126759     PISSN: 00306665     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.otc.2007.10.005     Document Type: Review

References (71)

1. American Cancer Society. Available at: (www.cancer.org). Accessed October 28, 2007.
2. Forastiere A., Koch W., Trotti A., et al. Head and neck cancer. N Engl J Med 345 (2001) 1890-1900
3. Minn H., Paul R., and Ahonen A. Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose. J Nucl Med 29 9 (1998) 1521-1525
4. Branstetter B.F., Blodgett T.M., Zimmer L.A., et al. Head and neck malignancy: Is PET/CT more accurate than PET or CT alone?. Radiology 235 2 (2005) 580-586
5. Schoder H., Yeung H.W.D., Gonen M., et al. Head and neck cancer: clinical usefulness and accuracy of PET/CT image fusion. Radiology 231 (2004) 65-72
6. Bar-Shalom R., Yefremov N., Guralnik L., et al. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. J Nucl Med 44 8 (2003) 1200-1209
7. Zanation A.M., Sutton D.K., Couch M.E., et al. Use, accuracy and implications for patient management of [18F]-2-fluorodeoxyglucose-positron emission/computerized tomography for head and neck tumors. Laryngoscope 115 7 (2005) 1186-1190
8. Blodgett T.M., Fukui M.B., Snyderman C.H., et al. Combined PET-CT in the head and neck part 1. Radiographics 25 4 (2005) 897-912
9. Greene F.L., Page D.L., Fleming I.D., et al. AJCC Cancer Staging Manual. 6th edition (2002), Springer-Verlag, New York
10. Prehn R.B., Pasic T.R., Harari P.M., et al. Influence of computed tomography on pretherapeutic tumor staging in head and neck cancer patients. Otolaryngol Head Neck Surg 119 6 (1998) 628-633
11. Laubenbacher C., Saumweber D., Wagner-Manslau C., et al. Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging head and neck sqamous-cell carcinomas. J Nucl Med 36 10 (1995) 1747-1757
12. Wong W.L., Chevretton E., McGurk M., et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol 22 3 (1997) 209-214
13. Shah N.P., Workman R.B., Coleman R.E., et al. "PET and PET/CT in head and neck cancer". In: Workman R.B., and Coleman R.E. (Eds). PET/CT essentials for clinical practice (2006), Springer, New York 104-129
14. Hannah A., Scott A.M., Tochon-Danguy H., et al. Evaluation of 18 F-fluorodeoxyglucose positron emission tomography and computed tomography with histopathologic correlation in the initial staging of head and neck cancer. Ann Surg 236 (2002) 208-217
15. Schmid D.T., Stoeckli S.J., Bandhauer F., et al. Impact of positron emission tomography on the initial staging and therapy in locoregional advanced squamous cell carcinoma of the head and neck. Laryngoscope 113 (2003) 888-891
16. Don D.M., Anzai Y., Lufkin R.B., et al. Evaluation of cervical lymph node metastases in squamous cell carcinoma of the head and neck. Laryngoscope 105 7 (1995) 669-674
17. King A.D., Tse G.M.K., Ahuja A.T., et al. Necrosis in metastatic neck nodes: diagnostic accuracy of CT, MR imaging and US. Radiology 230 3 (2004) 720-726
18. Adams S., Baum R.P., Stuckensen T., et al. Prospective comparison of 18F-FDG-PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 25 9 (1998) 1255-1260
19. Schwartz D.L., Ford E., Rajendran J., et al. FDG-PET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 61 (2005) 129-136
20. Koshy M., Paulino A.C., Howell R., et al. F-18 FDG PET-CT fusion in radiotherapy treatment planning for head and neck cancer. Head Neck 27 6 (2005) 494-502
21. Ha P.K., Hdeib A., Goldenberg D., et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 132 1 (2006) 12-16
22. Goerres G.W., Schmid D.T., Gratz K.W., et al. Impact of whole body positron emission tomography on initial staging and therapy in patients with squamous cell carcinoma of the oral cavity. Oral Oncol 39 6 (2003) 547-551
23. Brouwer J., de Bree R., Hoekstra O.S., et al. Screening for distant metastases in patients with head and neck cancer: is chest computed tomography sufficient?. Laryngoscope 115 10 (2005) 1813-1817
24. Reiner B., Siegel E., Sawyer R., et al. The impact of routine CT of the chest on the diagnosis and management of newly diagnosed squamous cell carcinoma of the head and neck. Am J Roentgenol 169 3 (1997) 667-671
25. de Bree R., Deurloo E.E., Snow G.B., et al. Screening for distant metastases in patients with head and neck cancer. Laryngoscope 110 3 Pt 1 (2000) 397-401
26. Troell R.J., and Terris D.J. Detection of metastases from head and neck cancers. Laryngoscope 105 3 (1995) 247-250
27. Teknos T.N., Rosenthal E.L., Lee D., et al. Positron emission tomography in the evaluation of stage III and IV head and neck cancer. Head Neck 23 12 (2001) 1056-1060
28. Quon A., Fischbein N.J., McDougall I.R., et al. Clinical role of 18F-FDG PET/CT in the management of squamous cell carcinoma of the head and neck and thyroid carcinoma. J Nucl Med 48 1 (2007) 58S-67S
29. Johansen J., Eigtved A., Buchwald C., et al. Implication of 18F-fluoro-2-deoxy-D-glcose positron emission tomography on management of carcinoma of unknown primary in the head and neck: a Danish cohort study. Laryngoscope 112 11 (2002) 2009-2014
30. Jungehulsing M., Scheidhauer K., Damm M., et al. 2(F)-fluoro-2-deoxy-D-glucose positron emission tomography is a sensitive tool for the detection of occult primary cancer (carcinoma of unknown primary syndrome) with head and neck lymph node manifestation. Otolaryngol Head Neck Surg 123 3 (2000) 294-301
31. Miller F.R., Hussey D., Beeram M., et al. Positron emission tomography in the management of unknown primary head and neck carcinoma. Arch Otolaryngol Head Neck Surg 131 7 (2005) 626-629
32. Rusthoven K.E., Koshy M., Paulino A.C., et al. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer 101 11 (2004) 2641-2649
33. Gutzeit A., Antoch G., Kuhl H., et al. Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology 234 1 (2005) 227-234
34. Schoder H., Carlson D.L., Kraus D.H., et al. 18f-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 47 (2006) 755-762
35. Layland M.K., Sessions D.G., Lenox J., et al. The influence of lymph node metastasis in the treatment of squamous cell carcinoma of the oral cavity, orophayrnx, larynx and hypopharynx: N0 versus N+. Larngoscope 115 4 (2005) 629-639
36. Stoekli S.J., Steinert H., Pfaltz M., et al. Is there a role for positron emission tomography with 18F-fluorodeoxyglucose in the initial staging of nodal negative oral and oropharyngeal squamous cell carcinoma. Head Neck 24 (2002) 345-349
37. Myers L.L., Wax M.K., Nabi H., et al. Positron Emission Tomography in the Evaluation of the N0 Neck. Laryngoscope 108 2 (1998) 232-236
38. Wang D., Schultz C.J., Jursinic P.A., et al. Initial experience of FDG-PET/CT guided IMRT of head and neck carcinoma. Int J Radiat Oncol Biol Phys 65 1 (2006) 143-151
39. Heron D.E., Andrade R.S., Flickinger J., et al. Hybrid PET-CT simulation for radiation treatment planning in head-and-neck cancers. A brief technical report. Int J Radiat Oncol Biol Phys 60 (2004) 1419-1424
40. Scarfone C., Laverly W.C., Cmelak A.J., et al. Prospective feasibility trial of radiotherapy target definition for head and neck cancer using 3-dimensional PET and CT imaging. J Nucl Med 45 (2004) 543-552
41. Nishioka T., Shiga T., Shirato H., et al. Image fusion between 18 FDG-PET and MRI/CT for radiotherapy planning of oropharyngeal and nasopharyngeal carcinomas. Int J Radiat Oncol Biol Phys 53 (2002) 1051-1057
42. Daisne J., Duprez T., Weynant B., et al. Impact of image coregistration with computed tomography (CT), magnetic resonance (MR), and positron emission tomography with fluorodeoxyglucose (FDG-PET) on delineation of GTV's in oropharyngeal, laryngeal and hypopharyngeal tumors. Int J Radiat Oncol Biol Phys 54 (2002) 15-16
43. Ciernik F., Dizendorf E., Baumert B.G., et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT) A feasibility study. Int J Radiat Oncol Biol Phys 52 (2003) 853-863
44. Gourin C.G., Williams H.T., Seabolt W.N., et al. Utility of positron emission tomography-computed tomography in identification of residual nodal disease after chemoradiation for advanced head and neck cancer. Laryngoscope 116 5 (2006) 705-710
45. Yao M., Smith R.B., Graham M.M., et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 63 (2005) 991-999
46. Andrade R.S., Heron D.E., Degirmenci B., et al. Post-treatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 65 5 (2006) 1315-1322
47. Goerres G.W., Schmid D.T., Bandhauer F., et al. Positron emission tomography in the early follow-up of advanced head and neck cancer. Arch Otolaryngol Head Neck Surg 130 (2004) 105-109
48. Porceddu S.V., Jarmolowski E., Hicks R.J., et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)-radiotherapy in head and neck cancer. Head Neck 27 (2005) 175-181
49. Zimmer L.A., McCook B., Meltzer C., et al. The use of combined PET/CT for localizing recurrent head and neck cancer: the Pittsburgh experience. Ear Nose Throat J 84 2 (2005) 104,106,108-110
50. Andrade R.S., Heron D.E., Degirmenci B., et al. Post-treatment assessment of response using FDG-PET/CT for patients treated with definitive radiation therapy for head and neck cancers. Int J Radiat Oncol Biol Phys 65 (2006) 1315-1322
51. Ryan W.R., Fee W.E., Le Q.T., et al. Positron-emission tomography for surveillance of head and neck cancer. Laryngoscope 115 (2005) 645-650
52. Brkovich V.S., Miller F.R., Karnad A.B., et al. The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Laryngoscope 116 (2006) 855-858
53. Nayak JV, Walvekar RR, Andrade RS, et al. Deferring planned neck dissection after chemoradiation therapy in stage IV head and neck cancer: the utility of PET/CT. American head and neck society annual meeting & research workshop on the biology, prevention and treatment of head and neck cancer, August 2006.
54. Perlow A., Bui C., Shreve P., et al. High incidence of chest malignancy detected by FDG PET in patients suspected of recurrent squamous cell carcinoma of the upper aerodigestive tract. J Comput Assist Tomogr 28 5 (2004) 704-709
55. de Visscher A.V., and Manni J.J. Routine long-term follow-up in patients treated with curative intent for squamous cell carcinoma of the larynx, pharynx, and oral cavity. Does it make sense?. Arch Otolaryngol Head Neck Surg 120 9 (1994) 934-939
56. Leon X., Quer M., Diez S., et al. Second neoplasm in patients with head and neck cancer. Head Neck 21 3 (1999) 204-210
57. Helal B.O., Merlet P., Toubert M.E., et al. Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. J Nucl Med 42 (2001) 1464-1469
58. Nanni C., Rubello D., Fanti S., et al. Role of 18F-FDG-PET and PET/CT imaging in thyroid cancer. Biomed Pharmacother 60 8 (2006) 409-413
59. Palmedo H., Bucerius J., Joe A., et al. Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. J Nucl Med 47 4 (2006) 616-624
60. Szakall Jr. S., Esik O., Bajzik G., et al. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43 1 (2002) 66-71
61. Bockisch A., Brandt-Mainz K., Gorges R., et al. Diagnosis in medullary thyroid cancer with [18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 30 (2003) 22-25
62. Schaefer N.G., Hany T.F., Taverna C., et al. Non-Hodgkin lymphoma and Hodgkin disease: coregistered FDG PET and CT at staging and restaging-do we need contrast-enhanced CT?. Radiology 232 3 (2004) 823-829
63. Swetter S.M., Carroll L.A., Johnson D.L., et al. Positron emission tomography is superior to computed tomography for metastatic detection in melanoma patients. Ann Surg Oncol 9 7 (2002) 646-653
64. Steinert H.C., Huch Boni R.A., Buck A., et al. Malignant melanoma: staging with whole-body positron emission tomography and 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 195 3 (1995) 705-709
65. Strobel K., Dummer R., Husarik D.B., et al. High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases. Radiology 244 2 (2007) 566-574
66. Brun E., Ohlsson T., Erlandsson K., et al. Early prediction of treatment outcome in head and neck cancer with 2-18FDG PET. Acta Oncol 36 (1997) 741-747
67. Kitagawa Y., Sadato N., Azuma H., et al. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms. J Nucl Med 40 (1999) 1132-1137
68. Allal A.S., Dulguerov P., Allaoua M., et al. Standardized uptake value of 2-[(18)F]fluoro-2-deoxy-D-glucose in predicting outcome in head and neck carcinomas treated by radiotherapy with or without chemotherapy. J Clin Oncol 20 (2002) 1398-1404
69. Huang S.C. Anatomy of SUV: standardized uptake value. Nucl Med Biol 27 (2000) 643-646
70. Nakamoto Y., Bennett B., Dara P., et al. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 227 (2003) 817-824
71. Blodgett T.M., Casagranda B., Townsend D.W., et al. Issues, controversies, and clinical utility of combined PET/CT imaging: what is the interpreting physician facing?. AJR Am J Roentgenol 184 Suppl 5 (2005) S138-S145